Our profiling and comparison with the steps of conolidine and cannabidiol with recognized pharmacological brokers predicted a MOA shared with Cav2.2 channel blocker, ω-conotoxin CVIE. 2020). ACKR3 features for a 'scavenger' that 'traps' the secreted opioids and stops them from binding on the classical receptors, thereby dampening their analgesic https://prussiaq456gvr1.bloggazzo.com/profile